Clinical Trials

80 enrolled

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT06184750 2026-03-18

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

200 enrolled

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT06075953 2026-03-16

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

400 enrolled

Carcinoma, Intraductal, Noninfiltrating

NCT06218303 2026-03-12

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

Phase 1 Recruiting

50 enrolled

Carcinoma, Intraductal, Noninfiltrating

NCT04852887 2026-03-03

DEBRA

1,670 enrolled

Breast Neoplasms

NCT06434064 2026-03-02

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

30 enrolled

Triple Negative Breast Neoplasms

NCT06179303 2026-02-27

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

60 enrolled

Anatomic Stage III Breast Cancer AJCC v8

NCT06507618 2026-02-24

POWER II

354 enrolled

Breast Neoplasms

NCT06348134 2026-02-17

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

74 enrolled

Breast Neoplasms

NCT07019363 2026-01-21

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

1,903 enrolled

Breast Neoplasms

NCT05501704 2026-01-07

ETHAN - ET for Male BC

60 enrolled

Phase EARLY_PHASE1 Recruiting

Breast Neoplasms, Male

NCT04174352 2025-12-22

FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer

12 enrolled

ERα+ Breast Cancer

NCT05035836 2025-12-22

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

20 enrolled

Breast Neoplasms

NCT06364267 2025-11-18

BabyTears

140 enrolled

Breast Neoplasms

NCT04569747 2025-11-13

ADEPT

375 enrolled

Breast Neoplasms

NCT07190443 2025-09-29

AURA

290 enrolled

Breast Neoplasms

NCT05512364 2025-08-19

TREAT ctDNA

220 enrolled

Breast Neoplasms

NCT02476786 2025-07-28

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

50 enrolled

Breast Neoplasms

NCT05952557 2025-06-19

CAMBRIA-2

5,500 enrolled

Breast Neoplasms

NCT05472792 2025-05-23

CAMERAN

90 enrolled

Breast Neoplasms

NCT03011684 2025-05-08

TALES

309 enrolled

Breast Neoplasms, Infertility

NCT04985266 2024-12-05

TRAK-ER

1,100 enrolled

ER+ Breast Cancer

NCT05891093 2024-02-08

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

766 enrolled

Breast Neoplasms

NCT05780567 2023-04-21

Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer

1,946 enrolled

Breast Neoplasms

NCT02062489 2022-04-27

Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients

688 enrolled

Breast Neoplasms

NCT04666961 2022-04-22

HORNEO01

262 enrolled